Minghao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minghao Xu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Ning Ren
Fudan University
31 shared publications - Ying-Hao Shen
Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
31 shared publications - Zhiqiu Hu
Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
31 shared publications - Chenhao Zhou
Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China
30 shared publications - Jialei Weng
Department of Surgical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
30 shared publications - Qiongzhu Dong
Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer, Shanghai Municipal Health Commission (SMHC), Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University, China
30 shared publications
Latest Publications
- Open Access
- 2 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.
- 2 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
Open AccessThe MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.
- Open Access
- 5 November 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (11) , e010422
WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy
Background Immune checkpoint inhibitors (ICIs) are therapeutically effective for hepatocellular carcinoma (HCC) but are individually selective. This study examined the role of specific common fragile sites (CFSs) related gene in HCC immunotherapy. Methods We analyzed HCC tissues using next-generation sequencing and flow cytometry via time-of-flight technology. A humanized orthotopic HCC mouse model, an in vitro co-culture system, untargeted metabolomics and a DNA pulldown assay were used to examine the function and mechanism of WWOX in the tumor immune response. Results WWOX was the most upregulated CFS-related gene in HCC patients responsive to ICIs. WWOX deficiency renders HCC resistant to PD-1 treatment in humanized orthotopic HCC mouse model. Macrophage infiltration is increased and CD8 T-cell subset infiltration is decreased in WWOX-deficient HCC patients. HCC-derived oleic acid (OA) promotes macrophage conversion to an immunosuppressive phenotype. Mechanistically, WWOX deficiency promoted OA synthesis primarily via competitive binding of NME2 with KAT1, which promoted acetylation of NME2 at site 31 and inhibited NME2 binding to the SCD5 promoter region. Pharmacological blockade of SCD5 enhanced the antitumor effects of anti-PD-1 therapy. Conclusions WWOX is a key factor for immune escape in HCC patients, which suggests its use as a biomarker for stratified treatment with ICIs in clinical HCC patients.
- 5 November 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (11) , e010422
Open AccessWWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy
Background Immune checkpoint inhibitors (ICIs) are therapeutically effective for hepatocellular carcinoma (HCC) but are individually selective. This study examined the role of specific common fragile sites (CFSs) related gene in HCC immunotherapy. Methods We analyzed HCC tissues using next-generation sequencing and flow cytometry via time-of-flight technology. A humanized orthotopic HCC mouse model, an in vitro co-culture system, untargeted metabolomics and a DNA pulldown assay were used to examine the function and mechanism of WWOX in the tumor immune response. Results WWOX was the most upregulated CFS-related gene in HCC patients responsive to ICIs. WWOX deficiency renders HCC resistant to PD-1 treatment in humanized orthotopic HCC mouse model. Macrophage infiltration is increased and CD8 T-cell subset infiltration is decreased in WWOX-deficient HCC patients. HCC-derived oleic acid (OA) promotes macrophage conversion to an immunosuppressive phenotype. Mechanistically, WWOX deficiency promoted OA synthesis primarily via competitive binding of NME2 with KAT1, which promoted acetylation of NME2 at site 31 and inhibited NME2 binding to the SCD5 promoter region. Pharmacological blockade of SCD5 enhanced the antitumor effects of anti-PD-1 therapy. Conclusions WWOX is a key factor for immune escape in HCC patients, which suggests its use as a biomarker for stratified treatment with ICIs in clinical HCC patients.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 4867-4881
The Prognostic Significance of CTSV Expression in Patients with Hepatocellular Carcinoma
Purpose: Cathepsin V (CTSV) is a cysteine protease peptidase, which is typically upregulated in cancer and is associated with various oncogenic processes, such as angiogenesis, proliferation, apoptosis, and invasion. The study explored the role of CTSV in hepatocellular carcinoma (HCC) and its potential as a potential biomarker. Patients and Methods: This study collected tumor and peritumoral archived specimens from 180 HCC patients who underwent surgical resection at Zhongshan Hospital, Fudan University (Shanghai, China) between 2009 and 2010. We extracted data from the TCGA and GEO databases and conducted differential expression analysis, univariate Cox regression, and Kaplan-Meier analysis. Ultimately, we determined that CTSV may emerge as a potential biomarker. Then, immunohistochemical staining for CTSV was performed on tumors and adjacent tissues of HCC patients, and a Cox proportional hazards model was constructed to evaluate the prognostic significance of CTSV expression levels. Applied functional enrichment analysis to reveal the underlying molecular mechanisms. Utilized ssGSEA enrichment analysis and TIMER2.0 algorithm to explore the correlation between CTSV expression and immune cells in HCC. In vitro and in vivo experiments were conducted using human liver cancer cell lines to further validate the clinical application value of CTSV. Results: In this study, we observed that CTSV expression was notably elevated in HCC (P < 0.001), and identified a significant association between elevated CTSV expression and reduced overall survival rates in patients. In vitro and in vivo experiments indicated that CTSV knockdown could significantly inhibit the proliferation, migration, and invasion of liver cancer cells, and it was found that the combination of CTSV knockdown with PD-1 inhibitors might enhance the therapeutic effect of PD-1 inhibitors in HCC. Conclusion: CTSV serves as a standalone negative prognostic indicator and possesses clinical significance in HCC.
- 1 October 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 4867-4881
Open AccessThe Prognostic Significance of CTSV Expression in Patients with Hepatocellular Carcinoma
Purpose: Cathepsin V (CTSV) is a cysteine protease peptidase, which is typically upregulated in cancer and is associated with various oncogenic processes, such as angiogenesis, proliferation, apoptosis, and invasion. The study explored the role of CTSV in hepatocellular carcinoma (HCC) and its potential as a potential biomarker. Patients and Methods: This study collected tumor and peritumoral archived specimens from 180 HCC patients who underwent surgical resection at Zhongshan Hospital, Fudan University (Shanghai, China) between 2009 and 2010. We extracted data from the TCGA and GEO databases and conducted differential expression analysis, univariate Cox regression, and Kaplan-Meier analysis. Ultimately, we determined that CTSV may emerge as a potential biomarker. Then, immunohistochemical staining for CTSV was performed on tumors and adjacent tissues of HCC patients, and a Cox proportional hazards model was constructed to evaluate the prognostic significance of CTSV expression levels. Applied functional enrichment analysis to reveal the underlying molecular mechanisms. Utilized ssGSEA enrichment analysis and TIMER2.0 algorithm to explore the correlation between CTSV expression and immune cells in HCC. In vitro and in vivo experiments were conducted using human liver cancer cell lines to further validate the clinical application value of CTSV. Results: In this study, we observed that CTSV expression was notably elevated in HCC (P < 0.001), and identified a significant association between elevated CTSV expression and reduced overall survival rates in patients. In vitro and in vivo experiments indicated that CTSV knockdown could significantly inhibit the proliferation, migration, and invasion of liver cancer cells, and it was found that the combination of CTSV knockdown with PD-1 inhibitors might enhance the therapeutic effect of PD-1 inhibitors in HCC. Conclusion: CTSV serves as a standalone negative prognostic indicator and possesses clinical significance in HCC.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Representative IHC staining images showing the expressions of SLAMF7 and CCL2 in HCC samples. Scale bar: 200 μm (left) and 20 μm (right). (B) The prognostic prediction performances of SLAMF7 in combination with CCL2 for OS and DFS in our Fudan LCI HCC cohort.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Representative IHC staining images showing the expressions of SLAMF7 and CCL2 in HCC samples. Scale bar: 200 μm (left) and 20 μm (right). (B) The prognostic prediction performances of SLAMF7 in combination with CCL2 for OS and DFS in our Fudan LCI HCC cohort.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Top: Schematic showing the administration schedule of clophosome in the indicated orthotopic HCC mouse models. Bottom: Gross appearance of the liver bearing Hepa1-6 tumors in the indicated treatment groups. (B) The tumor weight and tumor volume of each group at the study endpoint (5 mice per group). NS, not significant, **P<0.01, and ***P<0.001, one-way ANOVA with a post hoc LSD test.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Top: Schematic showing the administration schedule of clophosome in the indicated orthotopic HCC mouse models. Bottom: Gross appearance of the liver bearing Hepa1-6 tumors in the indicated treatment groups. (B) The tumor weight and tumor volume of each group at the study endpoint (5 mice per group). NS, not significant, **P<0.01, and ***P<0.001, one-way ANOVA with a post hoc LSD test.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
Supplementary materials and methods
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
Supplementary materials and methods
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (C-D) Flow cytometry analysis of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells in the presence of recombinant CCL2 protein or CCL2 neutralizing antibody. (E-F) Chemotaxis assays showing the effect of CCL2 signaling on SLAMF7-regulated migration of macrophages using the indicated treatments. (G) Left: Gross appearance of the liver bearing orthotopic HCC tumors in the indicated treatment groups. Right: The tumor weight and tumor volume of each group (5 mice per group). (H) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD11b+ F4/80+ CD206+ macrophages in the indicated treatment groups. *P<0.05, **P<0.01, and ***P<0.001, One-way ANOVA with a post hoc LSD test (or Student’s t test in part A-B). Experiments were repeated three time and results were present as the mean ± SD.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Immunoblot assays showing the phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (B) Flow cytometry analyses of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells. (C) Chemotaxis assays showing the effect of supernatants from the indicated coculture systems on the migration abilities of THP-1-differentiated macrophages. Scale bar: 100 μm. (D) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (E) Immunoblot assays of phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (F) ChIP-qPCR analyses of ATF2 binding to the CCL2 gene promoter in HCC cell lines with SLAMF7 overexpression and knockdown. (G) Immunoblot assays of SLAMF7, and ATF2 protein levels in the indicated HCC cells. **P<0.01, and ***P<0.001, Student’s t test. Experiments were repeated three time and results were present as the mean ± SD.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Immunoblot assays showing the phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (B) Flow cytometry analyses of CD80 and CD206 expressions in THP-1-differentiated macrophages cocultured with the indicated HCC cells. (C) Chemotaxis assays showing the effect of supernatants from the indicated coculture systems on the migration abilities of THP-1-differentiated macrophages. Scale bar: 100 μm. (D) qPCR and ELISA analyses of CCL2 transcriptional and secretory levels in the indicated HCC cells. (E) Immunoblot assays of phosphorylated or non-phosphorylated ERK1/2, p38, and JNK proteins in the indicated HCC cells. (F) ChIP-qPCR analyses of ATF2 binding to the CCL2 gene promoter in HCC cell lines with SLAMF7 overexpression and knockdown. (G) Immunoblot assays of SLAMF7, and ATF2 protein levels in the indicated HCC cells. **P<0.01, and ***P<0.001, Student’s t test. Experiments were repeated three time and results were present as the mean ± SD.